Thermo Fisher Scientific and UCSF open cell therapy manufacturing facility
In collaboration with Thermo Fisher Scientific, UCSF has opened a new manufacturing site aimed at accelerating advanced cell and gene therapies for cancer, rare diseases, and other illnesses.
The University of California, San Francisco and Thermo Fisher Scientific have opened a new cGMP manufacturing facility specialising in advanced cell therapies for the treatment of cancer, rare diseases, and other difficult-to-treat illnesses. The facility sits adjacent to the UCSF Medical Center’s Mission Bay campus.
First announced in 2021, the partnership between Thermo Fisher and UCSF will enable scientists, clinicians, and patients closer access to a manufacturing site, and potentially demonstrate how the development of breakthrough treatments may be expedited with increased access to state-of-the-art facilities. The initial focus of the site will be the development of treatments for glioblastomas, multiple myeloma, and other forms of cancer utilising updated approaches on CAR T and CRISPR technologies.
Executive VP and COO of Thermo Fisher Michel Lagarde stated: “Cell therapies represent a rapidly emerging field of biotechnology with tremendous promise for future therapeutic applications. With a record number of cell therapy approvals granted in the last 2 years, and CAR-T therapies becoming earlier treatment options, we’re in a golden age of biology where new technologies and partnerships are evolving and transforming clinical care.”
As part of Thermo Fisher’s global network of pharmaceutical and therapeutic services, including over 15 locations servicing cell and gene therapies, the facility will offer the UCSF community and other customers process and analytical capabilities, and clinical and commercial manufacturing services for advanced cell and gene therapies. Drug development, discovery, and commercialisation will also be accessible for those looking to benefit from Thermo Fisher’s therapeutic development capabilities with this San Francisco facility.
UCSF Chancellor, Sam Hawgood, commented on the site establishment: “UCSF is one of the top clinical sites for CAR-T treatment, and our scientists are leading the next generation of CAR-T therapy development. These approaches will be tested soon in patients with solid tumours like glioblastoma and later in other diseases, including autoimmunity.”
Source: Thermo Fisher Scientific Opens Cell Therapy Facility at University of California, San Francisco, to Accelerate Development of Breakthrough Therapies [Accessed March 27 2023] https://newsroom.thermofisher.com/newsroom/press-releases/press-release-details/2023/Thermo-Fisher-Scientific-Opens-Cell-Therapy-Facility-at-University-of-California-San-Francisco-to-Accelerate-Development-of-Breakthrough-Therapies/default.aspx
Stay up to date with the latest developments at CPHI Barcelona
Across the industry, businesses large and small are making huge strides forward. At CPHI Barcelona, you can hear from – and meet – representatives from all kinds of pharma enterprises. Find out how they're driving themselves forward and be inspired.
Your CPHI Barcelona pass gives you access to all conference sessions, as well as the chance to connect in-person with the global pharma supply chain from 24-26 October, at Fira Barcelona Gran Via. Browse the agenda and secure your pass today!
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance